Skip to main content

Tocilizumab (Actemra)

Tocilizumab is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis.

It binds soluble as well as membrane bound interleukin-6 receptors, hindering IL-6 from exerting its pro-inflammatory effects.

It is administered through intravenous infusion every month or subcutaneously every 2 weeks.

In 2016, it sold €125 million in Europe.

It has an immunogenicity rate of 0-16%.

Labs that test for drug level:

University of Tours
United Medix Labs

Labs that test for ADA titre:

United Medix Labs